| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Enzon Pharmaceuticals, Inc. |
| Information provided by: | Enzon Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00023166 |
Purpose
Studies of PEG-paclitaxel have been terminated
| Condition | Intervention | Phase |
|
Neoplasm Lymphomas Neoplasm Metastasis |
Drug: PEG-paclitaxel |
Phase I |
| MedlinePlus related topics: | Cancer Lymphoma |
| Drug Information available for: | Paclitaxel |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
None - Study has been terminated.
Contacts and Locations More Information
| Study ID Numbers: | PTX-5001 |
| First Received: | August 24, 2001 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00023166 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
|
